Eli Lilly says it's not making as much money off high-priced insulin as you might think, per the Wall Street Journal.
By the numbers: The list price for Humalog, Lilly's insulin, has risen 52% since 2014. It now stands at $594 per month.
- But, in newly released figures, Lilly says most of that increase in list prices has been funneled into pharmacy benefit managers' rebates, not its own bottom line.
- The net price for a month of Humalog — the price after accounting for rebates and discounts — has fallen slightly over the same period. It was $147 in 2014, and is now $135.
Yes, but: This will be cold comfort to the uninsured and people with high deductibles, for whom rising list prices matter a great deal, especially for a drug people depend on to stay alive.
Go deeper: The outrage over insulin prices
